ImmunoGen, Inc. Announces Presentations at Upcoming EORTC-NCI-AACR Symposium

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics using its Tumor-Activated Prodrug (TAP) technology, today announced that the posters listed below, which have ImmunoGen authors, will be presented at the 20th EORTC-NCI-AACR Symposium on “Molecular Targets and Cancer Therapeutics” to be held October 21-24, 2008 in Geneva, Switzerland. These posters will be presented in the poster session “Monoclonal antibodies and targeted toxins/nuclides” being held on Friday, October 24, 2008 from 12:00 – 2:00 PM CEST (6:00-8:00 AM EDT).